Nobuyuki Koga

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Squamous Cell Carcinoma

Prognostic Factors

Placebo Controlled

Top Venues

Journal of pain research

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Kazumasa Saigoh, Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Xiaoping Ning, Steve Barash, Yuki Isogai, Nobuyuki Koga
Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials. Journal of pain research 16 (2023)
Kazumasa Saigoh, Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Xiaoping Ning, Steve Barash, Yuki Isogai, Nobuyuki Koga
Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials. Journal of pain research 16 (2023)
Kazumasa Saigoh, Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Xiaoping Ning, Steve Barash, Yuki Isogai, Nobuyuki Koga
Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials. Journal of pain research 16 (2023)
Koichi Hirata, Takao Takeshima, Noboru Imai, Hisaka Igarashi, Masako Shiosakai, Masanobu Inage, Fumi Sakurai, Xiaoping Ning, Masami Nakai, Nobuyuki Koga
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home. Expert opinion on drug safety (2022)
Fumihiko Sakai, Norihiro Suzuki, Byung-Kun Kim, Yoshihisa Tatsuoka, Noboru Imai, Xiaoping Ning, Miki Ishida, Kaori Nagano, Katsuhiro Iba, Hiroyuki Kondo, Nobuyuki Koga
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 (7) (2021)
Fumihiko Sakai, Norihiro Suzuki, Xiaoping Ning, Miki Ishida, Chiharu Usuki, Katsuhiro Iba, Yuki Isogai, Nobuyuki Koga
Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study. Drug safety 44 (12) (2021)
Fumihiko Sakai, Norihiro Suzuki, Byung-Kun Kim, Hisaka Igarashi, Koichi Hirata, Takao Takeshima, Xiaoping Ning, Tomoko Shima, Miki Ishida, Katsuhiro Iba, Hiroyuki Kondo, Nobuyuki Koga
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 (7) (2021)